In late March Nova Eye Medical nabbed US FDA clearance for its updated iTrack surgical device to treat glaucoma and now the company has officially launched the treatment in the USA.

Used by eye surgeons in globally, iTrack is a minimally invasive glaucoma surgery (MIGS), a consumable surgical device that restores the eye’s natural outflow pathway to lower pressure inside the eye and to eliminate patient reliance on anti-glaucoma medications for mild-moderate glaucoma.

The iTrack Advance is the new generation canaloplasty device for canal-based glaucoma surgery.

The first successful surgery was completed with iTrack Advance on 11 April and since then first surgeries have been conducted by several key opinion leaders.

First sales recorded in April

The existing iTrack product is used by about 200 glaucoma surgeons in the US, with the company targeting initial sales to existing accounts – with the first sales of iTrack Advance recorded in April.

The company says feedback on device performance has been very positive, plus the market opportunity is wide open, with about 1200 glaucoma specialists in the country, and on top of that nearly 10,000 cataract and anterior segment surgeons.

“We are pleased with the support provided by our existing customers as we commence the commercial roll out,” Nova Eye (ASX:EYE) MD Tom Spurling said.

“We look forward to the acceleration of sales as we generate new customer interest.”

Following initial sales to existing customers, the sales team will continue to introduce iTrack Advance to the surgeons experienced with iTrack, who are familiar with the surgical technique and the efficacy of the original iTrack catheter.

This article was developed in collaboration with Nova Eye Medical Limited, a Stockhead advertiser at the time of publishing.

This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.